Proteomics International Develops Test for Prediction of Kidney Function Decline in Diabetes Patients, Shares Fall 6%

MT Newswires Live

Jun 23, 2025

Proteomics International Laboratories (ASX:PIQ) said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.

The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.

The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.

The firm's shares fell 6% in recent trading, reaching their lowest point in over five years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545693354"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545693354\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545693354?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 12:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545693354","market":"sg","top_or_hot":-1,"title":"Proteomics International Develops Test for Prediction of Kidney Function Decline in Diabetes Patients, Shares Fall 6%","media":"MT Newswires Live","content":"<html><body><p> Proteomics International Laboratories (ASX:PIQ) said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.</p><p>The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.</p><p>The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.</p><p>The firm's shares fell 6% in recent trading, reaching their lowest point in over five years.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proteomics International Develops Test for Prediction of Kidney Function Decline in Diabetes Patients, Shares Fall 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProteomics International Develops Test for Prediction of Kidney Function Decline in Diabetes Patients, Shares Fall 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-23 12:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Proteomics International Laboratories (ASX:PIQ) said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.</p><p>The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.</p><p>The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.</p><p>The firm's shares fell 6% in recent trading, reaching their lowest point in over five years.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7048","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545693354","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545693354","pubTimestamp":1750652774,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Proteomics International Laboratories  said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.The firm's shares fell 6% in recent trading, reaching their lowest point in o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7048":"生命科学工具和服务","BK7508":"医药生物股","PIQ.AU":"PROTEOMICS INTERNATIONAL LAB"},"translate_title":"Proteomics International开发出预测糖尿病患者肾功能下降的测试，股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PIQ.AU":0.9},"content_text":"Proteomics International Laboratories (ASX:PIQ) said it developed and released a next-generation PromarkerD test system, an immunoassay-based diagnostic for the prediction of kidney function decline in adults with type 2 diabetes, according to a Monday Australian bourse filing.The test can identify individuals at risk of diabetes-related chronic kidney disease up to four years before clinical symptoms appear, per the filing. It measures two plasma protein biomarkers, ApoA4 and CD5L, alongside age and estimated glomerular filtration rate to generate a personalized risk score.The test identified 86% of at-risk individuals, missed by the current standard-of-care estimated glomerular filtration rate and urinary albumin-to-creatinine ratio tests. In a clinical study with 948 participants, the test showed that the high-risk PromarkerD group demonstrated 44-fold greater odds of kidney decline compared with the low-risk group.The firm's shares fell 6% in recent trading, reaching their lowest point in over five years.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}